Cyclosporin-A differentially affects apoptosis during in vivo rat thymocyte maturation.
Maturation arrest and interference with selection are two well-documented effects of cyclosporin-A (CsA) on the thymus. We recently hypothesized that these effects are related and owing to the reduced T-cell receptor (TCR)-CD3 complex-mediated signal transduction in thymocytes upon CsA treatment. In this hypothesis, the maturation arrest is the result of the additional depletion of thymocytes that normally survive by positive selection, whereas the impaired self-tolerance induction is caused by an increased survival of thymocytes that normally undergo negative selection. In this view, it is anticipated that CsA differentially affects thymocyte apoptosis during in vivo thymocyte maturation. Indeed, we report in this study a strong increase in apoptotic cells in the thymic cortex on in situ analysis. Simultaneously, the number of apoptotic cells had decreased at the cortico-medullary zone which is held to be the site for negative selection. Rapamycin (Rapa) also interferes with thymocyte maturation by inhibiting cytokine-driven proliferation. Hence, Rapa preferentially affects the early maturational stages of thymocyte development and is considered not to alter thymocyte selection and subsequent apoptotic events. Indeed, the number of apoptotic events appears not to be altered. However, possibly owing to the decrease in cortical macrophages, the apoptotic cells revealed an atypical enumeration around blood vessels. Taken together, our results favour the hypothesis that the dominant effect of CsA on the thymus is the reduction of the TCR-CD3 complex-mediated signal transduction in thymocytes upon interaction with stromal cells. Furthermore, the preferential localization of apoptotic cells next to blood vessels upon Rapa administration may indicate that endothelial cells are a back-up system for the removal of apoptotic cells.
Damoiseaux
J G M C
JG
Department of Immunology, University of Maastricht, The Netherlands. jdam@limm.azm.nl
Defresne
M P
MP
Reutelingsperger
C P M
CP
Van Breda Vriesman
P J C
PJ
D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D001284:Atrophy; D002454:Cell Differentiation / Q000187:drug effects; D017637:Clonal Deletion / Q000187:drug effects; D016572:Cyclosporine / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D004730:Endothelium, Vascular / Q000502:physiology; D005260:Female; D007166:Immunosuppressive Agents / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D018448:Models, Immunological; D051381:Rats; D011917:Rats, Inbred Lew; D017260:Receptor-CD3 Complex, Antigen, T-Cell / Q000187:drug effects / Q000502:physiology; D017634:Self Tolerance / Q000187:drug effects; D015398:Signal Transduction / Q000187:drug effects; D020123:Sirolimus / Q000494:pharmacology; D013047:Specific Pathogen-Free Organisms; D013601:T-Lymphocytes / Q000166:cytology / Q000187:drug effects*; D013950:Thymus Gland / Q000187:drug effects / Q000473:pathology
D007166:Immunosuppressive Agents; D017260:Receptor-CD3 Complex, Antigen, T-Cell; D016572:Cyclosporine; D020123:Sirolimus